Iteos Therapeutics Inc
NASDAQ:ITOS
Iteos Therapeutics Inc
NASDAQ:ITOS
Price:
10.15
USD
Market Cap:
$448.7m
Income Statement
Earnings Waterfall
Iteos Therapeutics Inc
Iteos Therapeutics Inc
Income Statement
Iteos Therapeutics Inc
Iteos Therapeutics Inc
Currency: USD
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
104
N/A
|
345
+231%
|
497
+44%
|
539
+8%
|
454
-16%
|
268
-41%
|
128
-52%
|
86
-33%
|
67
-23%
|
13
-81%
|
0
N/A
|
35
N/A
|
35
N/A
|
35
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(30)
|
(45)
|
(56)
|
(76)
|
(88)
|
(100)
|
(113)
|
(122)
|
(132)
|
(141)
|
(147)
|
(151)
|
(160)
|
(164)
|
(173)
|
(180)
|
(185)
|
(195)
|
(166)
|
|
| Selling, General & Administrative |
(10)
|
(15)
|
(20)
|
(33)
|
(37)
|
(41)
|
(44)
|
(41)
|
(43)
|
(44)
|
(45)
|
(47)
|
(49)
|
(50)
|
(51)
|
(50)
|
(50)
|
(49)
|
(34)
|
|
| Research & Development |
(21)
|
(30)
|
(36)
|
(44)
|
(51)
|
(59)
|
(69)
|
(82)
|
(89)
|
(97)
|
(102)
|
(104)
|
(111)
|
(113)
|
(122)
|
(130)
|
(136)
|
(145)
|
(131)
|
|
| Operating Income |
(30)
N/A
|
(45)
-50%
|
(56)
-23%
|
(76)
-37%
|
17
N/A
|
245
+1 384%
|
384
+57%
|
417
+8%
|
322
-23%
|
126
-61%
|
(19)
N/A
|
(65)
-237%
|
(93)
-43%
|
(151)
-62%
|
(173)
-15%
|
(145)
+16%
|
(150)
-4%
|
(160)
-6%
|
(166)
-4%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
19
|
27
|
35
|
32
|
31
|
31
|
31
|
31
|
22
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(16)
|
|
| Total Other Income |
7
|
7
|
9
|
11
|
1
|
12
|
5
|
7
|
28
|
11
|
15
|
11
|
0
|
10
|
11
|
11
|
7
|
8
|
3
|
|
| Pre-Tax Income |
(23)
N/A
|
(38)
-64%
|
(46)
-22%
|
(66)
-41%
|
18
N/A
|
257
+1 366%
|
389
+52%
|
424
+9%
|
350
-18%
|
149
-58%
|
15
-90%
|
(27)
N/A
|
(58)
-117%
|
(109)
-87%
|
(131)
-20%
|
(102)
+22%
|
(112)
-9%
|
(120)
-7%
|
(157)
-30%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
(3)
|
(42)
|
(92)
|
(95)
|
(89)
|
(52)
|
(3)
|
(2)
|
(4)
|
(4)
|
(5)
|
(6)
|
(9)
|
(14)
|
(11)
|
|
| Income from Continuing Operations |
(23)
|
(38)
|
(46)
|
(66)
|
15
|
215
|
298
|
330
|
261
|
97
|
12
|
(28)
|
(62)
|
(113)
|
(135)
|
(108)
|
(121)
|
(134)
|
(168)
|
|
| Net Income (Common) |
(28)
N/A
|
(43)
-53%
|
(50)
-16%
|
(67)
-32%
|
15
N/A
|
215
+1 359%
|
298
+39%
|
330
+11%
|
261
-21%
|
97
-63%
|
12
-88%
|
(28)
N/A
|
(62)
-117%
|
(113)
-83%
|
(135)
-20%
|
(108)
+20%
|
(121)
-12%
|
(134)
-11%
|
(168)
-25%
|
|
| EPS (Diluted) |
-0.82
N/A
|
-1.24
-51%
|
-1.44
-16%
|
-1.9
-32%
|
0.39
N/A
|
5.68
+1 356%
|
7.81
+38%
|
8.76
+12%
|
6.92
-21%
|
2.56
-63%
|
0.32
-88%
|
-0.79
N/A
|
-1.72
-118%
|
-3.15
-83%
|
-3.78
-20%
|
-2.72
+28%
|
-2.81
-3%
|
-3.32
-18%
|
-3.87
-17%
|
|
Switch to:
Switch to:
See Also
Discover More
